Skye Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.15	5.88	68.42	1.26	1.24	8.98
Short-Term Investments	8.96	19.85	-	-	-	-
Cash & Short-Term Investments	17.11	25.74	68.42	1.26	1.24	8.98
Cash Growth	-71.11%	-62.38%	5345.16%	0.96%	-86.15%	263.77%
Other Current Assets	1.46	1.36	2.41	10.39	7.7	0.63
Total Current Assets	18.57	27.09	70.83	11.65	8.94	9.61
Net Property, Plant & Equipment	0.81	1.17	1.88	0.28	0.16	0.23
Other Long-Term Assets	0.04	0.05	0.05	0.01	0.01	0.01
Total Assets	19.42	28.31	72.76	11.94	9.11	9.86
Accounts Payable	3.94	2.03	0.57	0.96	1.79	0.9
Accrued Expenses	0.23	1.27	1.11	1.25	0.67	0.52
Short-Term Debt	0.25	-	-	4.37	1.85	1.97
Current Portion of Leases	0.06	0.19	0.18	0.07	0.08	0.08
Other Current Liabilities	5.92	4.71	2.47	7.25	7.72	0.44
Total Current Liabilities	10.4	8.21	4.34	13.9	12.12	3.91
Long-Term Leases	-	0.08	0.27	0.17	-	0.08
Total Long-Term Liabilities	-	0.08	0.27	0.17	-	0.08
Total Liabilities	10.4	8.29	4.61	14.07	12.12	3.99
Common Stock	0.04	0.03	0.03	0.01	0	0.48
Additional Paid-in Capital	208.36	206.87	199.07	102.24	63.73	52.64
Retained Earnings	-	-	-	-104.38	-66.74	-47.26
Shareholders' Equity	208.4	206.9	199.1	-2.13	-3.01	5.86
Total Liabilities & Equity	19.42	28.31	72.76	11.94	9.11	9.86
Total Debt	0.31	0.27	0.46	4.62	1.93	2.14
Net Cash (Debt)	16.8	25.46	67.96	-3.36	-0.68	6.85
Net Cash Growth	-34.03%	-62.53%	-	-	-	604.71%
Net Cash Per Share	0.42	0.64	1.86	-0.48	-0.31	4.21
Book Value	208.4	206.9	199.1	-2.13	-3.01	5.86
Book Value Per Share	5.25	5.22	5.46	-0.30	-1.35	3.61
Tangible Book Value	208.4	206.9	199.1	-2.13	-3.01	5.86
Tangible Book Value Per Share	5.25	5.22	5.46	-0.30	-1.35	3.61

SEC Filings: 10-K · 10-Q